touchIN CONVERSATION for touchONCOLOGY

Listen to Ms Nikolina Dodlek, an oncology nurse from Croatia, in conversation with Professor Sherko Kümmel, a leading medical oncologist from Germany. They respond to questions submitted by the HCP audience and provide their expert insights on the use of antibody–drug conjugates (ADCs) in the treatment of patients with HER2-positive breast cancer.

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Daiichi Sankyo Europe GmbH and AstraZeneca. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchoncology.com

touchPANEL DISCUSSION for touchONCOLOGY

Listen to a panel of leading experts discuss the latest evidence and clinical implications of recently approved treatments for relapsed/refractory follicular lymphoma (R/R FL), the importance of shared decision-making in treatment selection in the era of BsAb and CAR T-cell therapies, and the key considerations for treatment sequencing.

The experts

• Dr Matthew Lunning, University of Nebraska, Omaha, NE, USA,
• Professor Charalambos Andreadis, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA,
• Dr Tara Graff, Mission Cancer and Blood, Des Moines, IA, USA.

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.

For further information visit: https://touchoncologyime.org/evolving-treatment-paradigm-relapsed-refractory-follicular-lymphoma

touchPANEL DISCUSSION for touchHAEMATOLOGY

Listen to a panel of leading experts discuss the latest evidence and clinical implications of recently approved treatments for relapsed/refractory follicular lymphoma (R/R FL), the importance of shared decision-making in treatment selection in the era of BsAb and CAR T-cell therapies, and the key considerations for treatment sequencing.

The experts

• Dr Matthew Lunning, University of Nebraska, Omaha, NE, USA,
• Professor Charalambos Andreadis, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA,
• Dr Tara Graff, Mission Cancer and Blood, Des Moines, IA, USA.

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.

For further information visit: https://touchhaematologyime.org/evolving-treatment-paradigm-relapsed-refractory-follicular-lymphoma